特朗普的药品定价政策是对制药公司的重大打击

Core Viewpoint - Trump's "Most Favored Nation" drug pricing policy poses a significant threat to the pharmaceutical industry, although its political support in Congress remains uncertain [1] Industry Impact - Analysts from Bryan Garnier Research indicate that the policy could impact various Medicare programs, but the specifics are currently unclear [1] - The policy was previously introduced during Trump's first term in 2020 but was blocked by a federal judge and later rescinded by President Biden in 2021 [1]